MoonLake Immunotherapeutics Files 8-K on Feb 26

TL;DR

**MoonLake Immunotherapeutics just filed a routine 8-K, signaling standard compliance and disclosure.**

AI Summary

MoonLake Immunotherapeutics filed an 8-K on February 26, 2024, under Regulation FD Disclosure and Financial Statements and Exhibits. The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company, based in Zug, Switzerland, with a business phone of 41 415108022, has a CIK of 0001821586 and a SEC file number of 001-39630.

Why It Matters

This filing ensures MoonLake Immunotherapeutics is compliant with SEC regulations, providing transparency to investors about its ongoing operations and any material non-public information.

Risk Assessment

Risk Level: low — The 8-K filing is a routine disclosure and does not indicate any specific new risks or material events beyond standard reporting.

Key Players & Entities

• MoonLake Immunotherapeutics (company) — Registrant
• February 26, 2024 (date) — Date of Report
• 41 415108022 (dollar_amount) — Registrant's Telephone Number
• 001-39630 (dollar_amount) — Commission File Number
• 0001821586 (dollar_amount) — Central Index Key (CIK)

FAQ

Key Financial Figures

• $0.0001 — red Class A ordinary share, par value $0.0001 per share MLTX The Nasdaq Capital M

Filing Documents

• ea0200697-8k_moonlake.htm (8-K) — 24KB
• ea0200697ex99-1_moonlake.htm (EX-99.1) — 25KB
• image_001.jpg (GRAPHIC) — 3KB
• ex99-1_001.jpg (GRAPHIC) — 11KB
• ex99-1_002.jpg (GRAPHIC) — 6KB
• 0001213900-24-016737.txt ( ) — 257KB
• mltx-20240226.xsd (EX-101.SCH) — 3KB
• mltx-20240226_lab.xml (EX-101.LAB) — 33KB
• mltx-20240226_pre.xml (EX-101.PRE) — 22KB
• ea0200697-8k_moonlake_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On February 26, 2024, MoonLake Immunotherapeutics (the "Company") issued a press release announcing the successful outcome of its end-of-Phase 2 interactions with the U.S. Food and Drug Administration, as well as positive feedback from its interactions with the E.U. European Medicines Agency, with both regulatory bodies unanimously supporting the Company's proposed approach for advancing its Phase 3 program of the Nanobody sonelokimab in hidradenitis suppurativa. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibits are being furnished herewith: Exhibit Number Exhibit Title or Description 99.1 Press Release, dated February 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOONLAKE IMMUNOTHERAPEUTICS Date: February 26, 2024 By: /s/ Matthias Bodenstedt Name: Matthias Bodenstedt Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR